Daxor submits dual 510k/CLIA-waiver application to FDA for Daxor BVA

Daxor Corporation announces it has submitted its next-generation blood volume analyzer – Daxor BVA – to the U.S. Food and Drug Administration, FDA, via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company’s mission is to advance healthcare by enabling optimal fluid management. “Today marks a long-anticipated and momentous milestone in our continued commitment to our customers, patients, and to achieving our vision of optimal blood volume for all,” said Michael Feldschuh, Daxor’s CEO and President. “Funded under contract by the U.S. Department of Defense, our next-generation analyzer will deliver a level of speed, access, and accuracy to blood volume management that can significantly improve care and outcomes in medicine.”